A positive Signatera™ test detects tumour recurrence with over 98% certainty.
The Signatera™ test is highly sensitive. It is a personalised molecular residual tumour (MRT) test that uses circulating tumour DNA (ctDNA) in the blood for analysis.
Unique molecular genetic testing from blood!
Accurate results for early detection of tumours!
It influences the further treatment of the tumour!
The Signatera™ test can be used for all somatic tumour types
Using the Signatera™ test, early detection of molecular residual tumours has become an effective tool for improving cancer treatment outcomes. The Signatera™ test is designed individually for each patient to help identify tumour recurrence well before standard imaging procedures.
World-class diagnostics
In clinical studies, the Signatera™ test has shown an outstandingly high result in all solid tumours.
How the Signatera™ test works
Learn how the Signatera™ test works
Get blood
All you need to do to perform the Signatera™ test and monitor your progress is to take a blood sample.
MRT test based on your own tissue sample
We use a personalised genetic test based on the patient’s unique tumour mutation pattern.
Detection of tumour DNA circulating in the blood
Accurate identification of ctDNA in the body can be used to determine whether cancer cells are present in the body, even after treatment.
Our team
Prof. Dr. Péter Lakatos
PhD, DSc
Medical Director of Vascular Diagnostics, Deputy Director for Strategy at the Department of Internal Medicine and Oncology, Semmelweis University. He is an endocrinologist, an internist, author of more than 300 scientific articles, and is responsible for the development of several medical technologies, as well as one of the oldest operating genetic laboratories in Hungary.
Dr. János Kósa
PhD
Laboratory Director with decades of professional experience in running routine and research molecular genetics projects. For 14 years he was the founder, laboratory and managing director of the first private genetic laboratory service provider in Hungary, and is currently a senior research fellow at the Department of Internal Medicine and Oncology at Semmelweis University, in addition to VGx.
Dr. Bálint Tobiás
PhD
Deputy Director of the VGx Diagnostic Laboratory, he has over a decade of experience in organising and maintaining the professional operation of a molecular genetics laboratory. He has invested considerable effort in the development of a gene panel predicting the dignity of thyroid tumours, which is unique both nationally and internationally. He is also highly skilled in the field of next-generation prenatal and oncological genetic testing.
Opinions of professors, biologists
Tumour diagnosis well before imaging!
„A test with high sensitivity and specificity is needed to detect tumour recurrence before it becomes clinically symptomatic.
Signatera™ allows us to confidently identify patients with molecular relapse when the disease burden is so low that it cannot be detected by imaging.“ – Pusztai Lajos, MD, DPhil
Prof. Lakatos Péter
Semmelweis University – Department of Internal Medicine and Oncology
„Signatera opens up new possibilities in the treatment of endocrine tumours. We will be able to judge much better whether tumours have been removed, how effective chemotherapy treatment is, and detect tumour recurrence much earlier.”
Regular free information
For those interested in testing, our geneticists regularly provide online information where patients can ask questions.
Find your nearest blood collection point
Blood sampling is available after prior consultation not only in Budapest, but also in rural towns. You can find out about our sampling locations here.
Frequently Asked Questions (FAQ)
Based on our experience, we have collected the most frequently asked questions about the Signatera™ test. Read the questions and answers here.
Tumour markers are biochemical substances selectively produced by tumour cells that can be detected in the blood or other body fluids. Tumour markers are not the most suitable for screening due to their sensitivity, they are only confirmatory in themselves, as their accuracy is much lower than the Signatera™ test. So what the Signatera™ test detects, tumour marker tests may not be able to detect.
Not yet available. A particular diagnostic test takes a long time to be accepted for funding. In such cases, individual applications are possible.
The test can be performed in all solid tumours, regardless of stage. Simply put, a solid tumour is a tumour that does not originate from “blood cells”. It can be said that almost any tumour type other than haematological tumours fits the definition. Thus, there is a wide range where it can be applied.
Our latest articles
Updates, recent research, results
English post
–
Admin
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc convallis dolor nec vehicula ultrices. Quisque et libero a purus sagittis egestas. Phasellus eget lorem vel turpis placerat scelerisque nec ac leo. Quisque tincidunt magna id risus dignissim, in eleifend lacus auctor.
Have a question? Wondering if the Signatera™ test is right for you?
Contact us and we will answer your questions as soon as possible.
